{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:21:18Z","timestamp":1793823678653,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2022,7,29]]},"DOI":"10.1038\/s41388-022-02397-5","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T07:05:59Z","timestamp":1656745559000},"page":"3876-3885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair"],"prefix":"10.1038","volume":"41","author":[{"given":"Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florina-Nicoleta","family":"Grigore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9544-2570","authenticated-orcid":false,"given":"Clark C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-4942","authenticated-orcid":false,"given":"Qing","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-1738","authenticated-orcid":false,"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"2397_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"2397_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2017.10.017","volume":"184","author":"S Hombach-Klonisch","year":"2018","unstructured":"Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A, et al. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharm Ther. 2018;184:13\u201341.","journal-title":"Pharm Ther"},{"key":"2397_CR3","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21:v1\u2013v100.","journal-title":"Neuro Oncol"},{"key":"2397_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","volume":"11","author":"GJ Kitange","year":"2009","unstructured":"Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11:281\u201391.","journal-title":"Neuro Oncol"},{"key":"2397_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215:1287\u201399.","journal-title":"J Exp Med"},{"key":"2397_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","volume":"80","author":"T Reisl\u00e4nder","year":"2020","unstructured":"Reisl\u00e4nder T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell. 2020;80:21\u20138.","journal-title":"Mol Cell"},{"key":"2397_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-020-0198-7","volume":"5","author":"Z Cheng","year":"2020","unstructured":"Cheng Z, Dai T, He X, Zhang Z, Xie F, Wang S, et al. The interactions between cGAS-STING pathway and pathogens. Signal Transduct Target Ther. 2020;5:91.","journal-title":"Signal Transduct Target Ther"},{"key":"2397_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.tibs.2020.12.010","volume":"46","author":"N Vashi","year":"2021","unstructured":"Vashi N, Bakhoum SF. The evolution of STING signaling and its involvement in cancer. Trends Biochem Sci. 2021;46:446\u201360.","journal-title":"Trends Biochem Sci"},{"key":"2397_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19:133.","journal-title":"Mol Cancer"},{"key":"2397_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"MR de la Vega","year":"2018","unstructured":"de la Vega MR, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21\u201343.","journal-title":"Cancer Cell"},{"key":"2397_CR11","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1016\/j.jmb.2016.04.032","volume":"428","author":"D Pilla-Moffett","year":"2016","unstructured":"Pilla-Moffett D, Barber MF, Taylor GA, Coers J. Interferon-inducible GTPases in host resistance, inflammation and disease. J Mol Biol. 2016;428:3495\u2013513.","journal-title":"J Mol Biol"},{"key":"2397_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.bbrc.2017.11.050","volume":"495","author":"H Xu","year":"2018","unstructured":"Xu H, Sun L, Zheng Y, Yu S, Ou-Yang J, Han H, et al. GBP3 promotes glioma cell proliferation via SQSTM1\/p62-ERK1\/2 axis. Biochem Biophys Res Commun. 2018;495:446\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"2397_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13046-020-01641-8","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu J, Gao L, Zhan N, Xu P, Yang J, Yuan F, et al. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. J Exp Clin Cancer Res. 2020;39:137.","journal-title":"J Exp Clin Cancer Res"},{"key":"2397_CR14","doi-asserted-by":"publisher","first-page":"8877.","DOI":"10.3390\/ijms21228877","volume":"21","author":"Q Storozynsky","year":"2020","unstructured":"Storozynsky Q, Hitt MM. The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer. Int J Mol Sci. 2020;21:8877.","journal-title":"Int J Mol Sci"},{"key":"2397_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.molcel.2018.07.034","volume":"71","author":"G Dunphy","year":"2018","unstructured":"Dunphy G, Flannery SM, Almine JF, Connolly DJ, Paulus C, J\u00f8nsson KL, et al. Non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 mediates NF-\u03baB signaling after nuclear DNA damage. Mol Cell. 2018;71:745\u201360.e5.","journal-title":"Mol Cell"},{"key":"2397_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1096\/fj.11-189886","volume":"26","author":"A Nordmann","year":"2012","unstructured":"Nordmann A, Wixler L, Boergeling Y, Wixler V, Ludwig S. A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication. FASEB J. 2012;26:1290\u2013300.","journal-title":"FASEB J"},{"key":"2397_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0517-y","volume":"32","author":"L Ma","year":"2015","unstructured":"Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol. 2015;32:69.","journal-title":"Med Oncol"},{"key":"2397_CR18","doi-asserted-by":"publisher","first-page":"48081","DOI":"10.18632\/oncotarget.10129","volume":"7","author":"CR Rocha","year":"2016","unstructured":"Rocha CR, Kajitani GS, Quinet A, Fortunato RS, Menck CF. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget. 2016;7:48081\u201392.","journal-title":"Oncotarget."},{"key":"2397_CR19","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1073\/pnas.0700898104","volume":"104","author":"Y Liu","year":"2007","unstructured":"Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci USA. 2007;104:5205\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2397_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.cell.2016.09.030","volume":"167","author":"J Moscat","year":"2016","unstructured":"Moscat J, Karin M, Diaz-Meco MT. p62 in cancer: signaling adaptor beyond autophagy. Cell. 2016;167:606\u20139.","journal-title":"Cell."},{"key":"2397_CR21","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1038\/s41388-019-0956-6","volume":"38","author":"P P\u00f6l\u00f6nen","year":"2019","unstructured":"P\u00f6l\u00f6nen P, Jawahar Deen A, Leinonen HM, Jyrkk\u00e4nen HK, Kuosmanen S, Mononen M, et al. Nrf2 and SQSTM1\/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma. Oncogene. 2019;38:7473\u201390.","journal-title":"Oncogene."},{"key":"2397_CR22","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 2016;11:3214\u201325.","journal-title":"ACS Chem Biol"},{"key":"2397_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","volume":"216","author":"K Tretina","year":"2019","unstructured":"Tretina K, Park ES, Maminska A, MacMicking JD. Interferon-induced guanylate-binding proteins: guardians of host defense in health and disease. J Exp Med. 2019;216:482\u2013500.","journal-title":"J Exp Med"},{"key":"2397_CR24","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3892\/ijo.2020.5086","volume":"57","author":"L Cheng","year":"2020","unstructured":"Cheng L, Gou L, Wei T, Zhang J. GBP1 promotes erlotinib resistance via PGK1\u2011activated EMT signaling in non\u2011small cell lung cancer. Int J Oncol. 2020;57:858\u201370.","journal-title":"Int J Oncol"},{"key":"2397_CR25","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3389\/fonc.2019.01494","volume":"9","author":"J Zhao","year":"2019","unstructured":"Zhao J, Li X, Liu L, Cao J, Goscinski MA, Fan H, et al. Oncogenic role of guanylate binding protein 1 in human prostate cancer. Front Oncol. 2019;9:1494.","journal-title":"Front Oncol"},{"key":"2397_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ijc.23944","volume":"124","author":"DP Guimar\u00e3es","year":"2009","unstructured":"Guimar\u00e3es DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C, et al. Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer. 2009;124:272\u20139.","journal-title":"Int J Cancer"},{"key":"2397_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3726-2","volume":"17","author":"M Quintero","year":"2017","unstructured":"Quintero M, Adamoski D, Reis LMD, Ascen\u00e7\u00e3o CFR, Oliveira KRS, Gon\u00e7alves KA, et al. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC Cancer. 2017;17:727.","journal-title":"BMC Cancer"},{"key":"2397_CR28","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1084\/jem.20111102","volume":"208","author":"M Li","year":"2011","unstructured":"Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, et al. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med. 2011;208:2657\u201373.","journal-title":"J Exp Med"},{"key":"2397_CR29","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1038\/s41388-020-1348-7","volume":"39","author":"S Yu","year":"2020","unstructured":"Yu S, Yu X, Sun L, Zheng Y, Chen L, Xu H, et al. GBP2 enhances glioblastoma invasion through Stat3\/fibronectin pathway. Oncogene. 2020;39:5042\u201355.","journal-title":"Oncogene."},{"key":"2397_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-005-0026-3","volume":"57","author":"Z Duan","year":"2006","unstructured":"Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV. GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharm. 2006;57:25\u201333.","journal-title":"Cancer Chemother Pharm"},{"key":"2397_CR31","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/cas.12489","volume":"105","author":"M Fukumoto","year":"2014","unstructured":"Fukumoto M, Amanuma T, Kuwahara Y, Shimura T, Suzuki M, Mori S, et al. Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance. Cancer Sci. 2014;105:1351\u20139.","journal-title":"Cancer Sci"},{"key":"2397_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12282-012-0404-8","volume":"21","author":"P Godoy","year":"2014","unstructured":"Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, et al. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer. 2014;21:491\u20139.","journal-title":"Breast Cancer"},{"key":"2397_CR33","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/jcb.29358","volume":"121","author":"J Wang","year":"2020","unstructured":"Wang J, Min H, Hu B, Xue X, Liu Y. Guanylate-binding protein-2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel-resistant colorectal cancer cells by interfering Wnt signaling. J Cell Biochem. 2020;121:1250\u20139.","journal-title":"J Cell Biochem"},{"key":"2397_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Disco. 2020;10:26\u201339.","journal-title":"Cancer Disco"},{"key":"2397_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","volume":"14","author":"T Xia","year":"2016","unstructured":"Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 2016;14:282\u201397.","journal-title":"Cell Rep"},{"key":"2397_CR36","doi-asserted-by":"publisher","first-page":"e97858.","DOI":"10.15252\/embj.201797858","volume":"37","author":"T Prabakaran","year":"2018","unstructured":"Prabakaran T, Bodda C, Krapp C, Zhang BC, Christensen MH, Sun C, et al. Attenuation of cGAS-STING signaling is mediated by a p62\/SQSTM1-dependent autophagy pathway activated by TBK1. Embo J.2018;37:e97858.","journal-title":"Embo J."},{"key":"2397_CR37","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/s41418-019-0303-z","volume":"26","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Zhang ZY, Du H, Li SZ, Tu R, Jia YF, et al. DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. Cell Death Differ. 2019;26:2300\u201313.","journal-title":"Cell Death Differ"},{"key":"2397_CR38","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbrc.2019.08.113","volume":"518","author":"J Wu","year":"2019","unstructured":"Wu J, Zhang L, Li H, Wu S, Liu Z. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression. Biochem Biophys Res Commun. 2019;518:698\u2013705.","journal-title":"Biochem Biophys Res Commun"},{"key":"2397_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.redox.2018.04.015","volume":"17","author":"IG Ryoo","year":"2018","unstructured":"Ryoo IG, Choi BH, Ku SK, Kwak MK. High CD44 expression mediates p62-associated NFE2L2\/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance. Redox Biol. 2018;17:246\u201358.","journal-title":"Redox Biol"},{"key":"2397_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1004-x","volume":"19","author":"D Deng","year":"2019","unstructured":"Deng D, Luo K, Liu H, Nie X, Xue L, Wang R, et al. p62 acts as an oncogene and is targeted by miR-124-3p in glioma. Cancer Cell Int. 2019;19:280","journal-title":"Cancer Cell Int"},{"key":"2397_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-013-1260-x","volume":"116","author":"ZX Cong","year":"2014","unstructured":"Cong ZX, Wang HD, Zhou Y, Wang JW, Pan H, Zhang DD, et al. Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells. J Neurooncol. 2014;116:41\u20138.","journal-title":"J Neurooncol"},{"key":"2397_CR42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7555\/JBR.30.20160040","volume":"30","author":"A Paranjpe","year":"2016","unstructured":"Paranjpe A, Bailey NI, Konduri S, Bobustuc GC, Ali-Osman F, Yusuf MA, et al. New insights into estrogenic regulation of O(6)-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: co-degradation of ER-\u03b1 and MGMT proteins by fulvestrant or O(6)-benzylguanine indicates fresh avenues for therapy. J Biomed Res. 2016;30:393\u2013410.","journal-title":"J Biomed Res"},{"key":"2397_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03492-3","volume":"12","author":"X Yu","year":"2021","unstructured":"Yu X, Jin J, Zheng Y, Zhu H, Xu H, Ma J, et al. GBP5 drives malignancy of glioblastoma via the Src\/ERK1\/2\/MMP3 pathway. Cell Death Dis. 2021;12:203.","journal-title":"Cell Death Dis"},{"key":"2397_CR44","doi-asserted-by":"publisher","first-page":"55319","DOI":"10.18632\/oncotarget.19429","volume":"8","author":"M Li","year":"2017","unstructured":"Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, et al. CDK4\/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget. 2017;8:55319\u201331.","journal-title":"Oncotarget."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02397-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02397-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02397-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T02:42:33Z","timestamp":1700793753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02397-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":44,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,7,29]]}},"alternative-id":["2397"],"URL":"https:\/\/doi.org\/10.1038\/s41388-022-02397-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}